Rhythm Control for Management of Patients with Atrial Fibrillation: Balancing the Use of Antiarrhythmic Drugs and Catheter Ablation

Overview

Journal Clin Cardiol

Specialty Cardiology & Vascular Diseases

Date 2011 Jan 25

PMID 21259274

Citations 1

Authors

Juan F Viles-Gonzalez

Valentin Fuster

Jonathan Halperin

Hugh Calkins

Vivek Y Reddy

Affiliations

Soon will be listed here.

Abstract

Antiarrhythmic drug (AAD) therapy may be beneficial for patients with symptoms attributable to atrial fibrillation despite adequate rate control. The limited long-term efficacy of AAD and the relatively large proportion of patients discontinuing therapy because of side effects led to the development of nonpharmacological therapies to achieve rhythm control. Pressing questions remain about the effect of ablation therapy on long-term patient outcomes. Based on recent clinical trials and meta-analyses, ablation appears more effective and possibly safer than AAD for long-term maintenance of sinus rhythm in selected patients, but the evidence is insufficient to recommend ablation in preference to drug therapy as the first AAD therapy for the majority of patients in whom a rhythm control strategy is justified. Herein, we review the most current evidence supporting the use of AAD and catheter ablation in atrial fibrillation.

Citing Articles

Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group.

Fuster V, Bhatt D, Califf R, Michelson A, Sabatine M, Angiolillo D Circulation. 2012; 126(13):1645-62.

PMID: 23008471 PMC: 4086864. DOI: 10.1161/CIRCULATIONAHA.112.105908.

References

Le Heuzey J, De Ferrari G, Radzik D, Santini M, Zhu J, Davy J . A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010; 21(6):597-605. DOI: 10.1111/j.1540-8167.2010.01764.x. View

Wilber D, Pappone C, Neuzil P, de Paola A, Marchlinski F, Natale A . Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010; 303(4):333-40. DOI: 10.1001/jama.2009.2029. View

Kober L, Torp-Pedersen C, McMurray J, Gotzsche O, Levy S, Crijns H . Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008; 358(25):2678-87. DOI: 10.1056/NEJMoa0800456. View

Oral H, Pappone C, Chugh A, Good E, Bogun F, Pelosi Jr F . Circumferential pulmonary-vein ablation for chronic atrial fibrillation. N Engl J Med. 2006; 354(9):934-41. DOI: 10.1056/NEJMoa050955. View

Laughlin J, Kowey P . Dronedarone: a new treatment for atrial fibrillation. J Cardiovasc Electrophysiol. 2008; 19(11):1220-6. DOI: 10.1111/j.1540-8167.2008.01251.x. View

Fuster V, Ryden L, Cannom D, Crijns H, Curtis A, Ellenbogen K . ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for.... Circulation. 2006; 114(7):e257-354. DOI: 10.1161/CIRCULATIONAHA.106.177292. View

Pappone C, Rosanio S, Augello G, Gallus G, Vicedomini G, Mazzone P . Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol. 2003; 42(2):185-97. DOI: 10.1016/s0735-1097(03)00577-1. View

Anderson J, Gilbert E, Alpert B, Henthorn R, Waldo A, Bhandari A . Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide.... Circulation. 1989; 80(6):1557-70. DOI: 10.1161/01.cir.80.6.1557. View

Pappone C, Augello G, Sala S, Gugliotta F, Vicedomini G, Gulletta S . A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J Am Coll Cardiol. 2006; 48(11):2340-7. DOI: 10.1016/j.jacc.2006.08.037. View

10.

Noheria A, Kumar A, Wylie Jr J, Josephson M . Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch Intern Med. 2008; 168(6):581-6. DOI: 10.1001/archinte.168.6.581. View

11.

Pedersen O, BAGGER H, Keller N, Marchant B, Kober L, Torp-Pedersen C . Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation. 2001; 104(3):292-6. DOI: 10.1161/01.cir.104.3.292. View

12.

Wyse D, Waldo A, DiMarco J, Domanski M, Rosenberg Y, Schron E . A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347(23):1825-33. DOI: 10.1056/NEJMoa021328. View

13.

Torp-Pedersen C, Moller M, Kober L, SANDOE E, Egstrup K, Agner E . Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999; 341(12):857-65. DOI: 10.1056/NEJM199909163411201. View

14.

Davy J, Herold M, Hoglund C, Timmermans A, Alings A, Radzik D . Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. Am Heart J. 2008; 156(3):527.e1-9. DOI: 10.1016/j.ahj.2008.06.010. View

15.

Meinertz T, Lip G, Lombardi F, Sadowski Z, Kalsch B, Camez A . Efficacy and safety of propafenone sustained release in the prophylaxis of symptomatic paroxysmal atrial fibrillation (The European Rythmol/Rytmonorm Atrial Fibrillation Trial [ERAFT] Study). Am J Cardiol. 2002; 90(12):1300-6. DOI: 10.1016/s0002-9149(02)02867-9. View

16.

Roy D, Talajic M, Dorian P, Connolly S, Eisenberg M, Green M . Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000; 342(13):913-20. DOI: 10.1056/NEJM200003303421302. View

17.

Jais P, Cauchemez B, Macle L, Daoud E, Khairy P, Subbiah R . Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation. 2008; 118(24):2498-505. DOI: 10.1161/CIRCULATIONAHA.108.772582. View

18.

Tschuppert Y, Buclin T, Rothuizen L, Decosterd L, Galleyrand J, Gaud C . Effect of dronedarone on renal function in healthy subjects. Br J Clin Pharmacol. 2007; 64(6):785-91. PMC: 2198776. DOI: 10.1111/j.1365-2125.2007.02998.x. View

19.

Calkins H, Reynolds M, Spector P, Sondhi M, Xu Y, Martin A . Treatment of atrial fibrillation with antiarrhythmic drugs or radiofrequency ablation: two systematic literature reviews and meta-analyses. Circ Arrhythm Electrophysiol. 2009; 2(4):349-61. DOI: 10.1161/CIRCEP.108.824789. View

20.

Singh B, Connolly S, Crijns H, Roy D, Kowey P, Capucci A . Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007; 357(10):987-99. DOI: 10.1056/NEJMoa054686. View